Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + Disitamab vedotin ± Bevacizumab with chemoradiotherapy in cervical cancer
ChiCTR2600120786Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab, disitamab vedotin and bevacizumab in Cervical Cancer (CC) (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: 2-year disease-free survival rate. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
cadonilimabdisitamab vedotinbevacizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600120786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120786.